In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: FDA warning letter grace period

This article was originally published in The Gray Sheet

Executive Summary

FDA warning letter grace period: Proposal to give firms a 15-day response period after receiving an FDA-483 inspectional observation form prior to issuing a warning letter is slated for discussion at an April meeting of FDA's Field Committee. The change in policy would obviate issuance of a warning letter if a firm corrected all violations during the grace period ("The Gray Sheet" Dec. 22, I&W-5)...



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts